Investigation of the supportive therapy potential of propolis extract and Lactobacillus acidophilus LA-5 milk combination against breast cancer in mice

Cytokine ◽  
2022 ◽  
Vol 149 ◽  
pp. 155743
Author(s):  
Elif Onur ◽  
Gökhan Gurur Gökmen ◽  
Ayşe Nalbantsoy ◽  
Duygu Kışla
Keyword(s):  
Breast Cancer ◽  
Lactobacillus Acidophilus ◽  
Supportive Therapy ◽  
Propolis Extract

Pegfilgrastim-associated large-vessel vasculitis developed during adjuvant chemotherapy for breast cancer: A case report and review of the literature

2020 ◽  
Vol 26 (7) ◽  
pp. 1785-1790 ◽  
Author(s):  
Jun Nakamura ◽  
Tomoyo M Nishi ◽  
Shun Yamashita ◽  
Hiroaki Nakamura ◽  
Ken Sato ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Adjuvant Chemotherapy ◽  
Supportive Therapy ◽  
Granulocyte Colony Stimulating Factor ◽  
Review Of The Literature ◽  
Breast Cancer Chemotherapy ◽  
Prophylactic Use ◽  
Stimulating Factor ◽  
Rule Out

Introduction Granulocyte colony-stimulating factor (G-CSF) is widely used as a neutrophil supportive therapy in breast cancer chemotherapy. Common adverse events of G-CSF include bone pain, headache, and fatigue; however, reports of G-CSF-associated vasculitis are few. Case report A 66-year-old woman who had undergone surgery for breast cancer received adjuvant chemotherapy with prophylactic use of pegfilgrastim (peg-G). She developed peg-G-associated vasculitis 11 days after initially receiving peg-G. Management and outcome: Although various blood and culture tests were required to rule out other vasculitis syndromes and infections, her symptoms spontaneously disappeared without any treatment other than discontinuation of the causal drug. Discussion G-CSF-associated vasculitis is occasionally accompanied by severe complications such as aortic dissection and aneurysm formation. This case report is important to draw attention towards this rare and difficult-to-diagnosis adverse event of peg-G.

Analysis of pretreatment nonpharmacologic, pharmacologic factors, and yoga intervention on CINV outcomes in breast cancer patients undergoing adjuvant chemotherapy.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1093-1093
Author(s):  
Malur R. Usharani ◽  
Rao M. Raghavendra ◽  
Kodaganur Srinivasachar Gopinath ◽  
Ramesh Bilimagga S ◽  
Ravi B Diwakar ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Supportive Therapy ◽  
Nausea And Vomiting ◽  
Breast Cancer Patients ◽  
Anticipatory Nausea ◽  
Yoga Intervention ◽  
Antiemetic Regimen ◽  
Primary Predictor

1093 Background: Chemotherapy induced nausea and vomiting (CINV) is affected by both pretreatment patient factors, chemotherapy and antiemetic regimen and psychological interventions. In this study we evaluated the effects of mind body intervention such as yoga in modulating CINV outcomes controlled for the above factors. Methods: Chemotherapy naïve breast cancer patients with stage II and III disease participating in a randomized controlled trial comparing yoga (n=45) vs. supportive therapy (n=53) were assessed for CINV outcomes during adjuvant chemotherapy. Morrows Assessment of nausea and emesis was used to asses CINV symptoms including their frequency, severity and anticipatory nature. We developed a multiple regression analyses to test the role of intervention on CINV beyond that explained by the independent prognostic factors [age (<50/≥50 years), stage of disease (II vs III), menopausal status (pre vs post), antiemetic regimen (5HT3 antagonists vs. antidopaminergics), administration of anxiolytics (yes/ no) and type of chemotherapy regimen (FAC vs. CMF)] that were included in model A. Model B includes these six variables plus intervention (yoga vs. supportive therapy) in predicting nausea and vomiting outcomes. Results: Intervention emerged as a primary predictor for nausea frequency (β= -0.38, p=0.002), intensity (β= -0.44, p=0.001 ), anticipatory nausea frequency (β=-0.26 , p= 0.04) and intensity (β=-0.38 , p=0.004 ). Age group emerged as a primary predictor for anticipatory vomiting frequency (β=-0.39 , p=0.01 ) and secondary predictor for nausea frequency (β=-0.41, p= 0.006). Administration of anxiolytics emerged as a primary predictor for vomiting intensity (β=-0.40, p= 0.001) and secondary predictor for anticipatory nausea frequency (β=-0.26 , p= 0.05). Conclusions: Yoga intervention influences CINV outcomes when controlled for pretreatment and pharmacological factors during chemotherapy in breast cancer patients poorly controlled for nausea and vomiting.

Voice of Cancer Patients: Analysis of patient concerns regarding cognitive deficits associated with treatment for breast cancer.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 82-82
Author(s):  
Sangeeta Aggarwal ◽  
Mingfeng Liu ◽  
Rishi Sharma ◽  
Fred Yang ◽  
Ankit Gupta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Language Processing ◽  
Data Science ◽  
Strong Association ◽  
Supportive Therapy ◽  
Relevant Information ◽  
Cancer Therapies ◽  
Online Forums ◽  
Cancer Treatments ◽  
System A

82 Background: Patients undergoing breast cancer treatment often report Symptoms of Cognitive Deficit (SCD). Many of them share their experiences on online forums, which contain millions of freely shared messages that can be used to analyze these SCD. Unfortunately, this data is unstructured, making it difficult to analyze. In this project we organize this data using methods from Big Data Science (BDS) and analyze it by creating a Decision Support System (DSS): an interface that can be used by patients and providers to understand how SCD are associated with specific types – hormonal only (HT), chemo only (CT), or both (CT/HT) – of breast cancer therapies. Methods: We collected 3.5 million unique messages from 20 unrestricted breast cancer forums that provide clinically relevant information. We next built custom ontologies for breast cancer treatments, SCD, and supportive therapies. Then, we created a DSS using methods from BDS, including topic modeling, information retrieval, and natural language processing to extract the relevant data from these messages. We also used token windows and co-occurrence-based algorithms to associate treatment with SCD and supportive therapies. To use this system, a user provides disease-related parameters and the treatment. The DSS then gives the percentage of messages discussing SCD for a similar cohort of patients and the percentage of messages that discuss supportive therapies for each of these SCD. Results: We found 15719 messages that had strong association of SCD with treatments. 3355 messages were from HT patients, 5740 messages were from CT patients, and 9095 messages were from CT/HT patients. Among HT, 28.18% patients taking aromatase inhibitors and 19.20% taking tamoxifen associated SCD to HT. Among CT, 35.26% patient receiving taxane containing chemo associated SCD to CT. SCD worsened during HT for CT/HT patients. Suggestive therapy: 80 messages found Vitamin B12 and B6 useful, 65 suggested Acetyle-L-Carnitine, and 50 suggested playing word games. Conclusions: Using methods from BDS, our DSS reliably associates SCD with HT, CT and CT/CT, and suggests supportive therapies. More research is needed to evaluate the role of supportive therapy for SCD.

Dose-dense (DD) two-weekly docetaxel/doxorubicin/cyclophosphamide (TAC) with G-CSF support compared to standard adjuvant TAC in breast cancer patients

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11052-11052
Author(s):  
S. Z. Latifzadeh ◽  
M. Salimi ◽  
M. Naghnaeian ◽  
V. Entezari
Keyword(s):  
Breast Cancer ◽  
Liver Function ◽  
Supportive Therapy ◽  
Liver Function Tests ◽  
Breast Cancer Patients ◽  
Prophylactic Use ◽  
Dose Dense ◽  
Significant Disease ◽  
Disease Free ◽  
Grade Iii

11052 Background: TAC confers a significant disease free and overall survival benefits vs. FAC for patients with node positive breast cancer and prophylactic use of G-CSF is a reasonable supportive therapy to minimize myelosuppresive complications of this regimen. DD scheduling has shown improved clinical outcomes in breast cancer therapy. This study is trying to compare toxicities and tolerability of DD TAC with G-CSF support with TAC every 3 wks supported with G-CSF. Methods: Thirty seven patients were enrolled during the period 1/04 to 1/06. Cohort A (N=25) received six cycles of TAC (75/50/500 mg/m2 every 3 wks) plus GCSF started on day 5 and Cohort B (N=12) received six cycles of TAC (75/50/500 mg/m2 every 2 wks) plus GCSF started on day 2. All patients had normal cardiac, renal and liver function. Toxicities were evaluated by clinical assessment, CBC and liver function tests. Results: The incidence of febrile neutropenia was 15.8% and 16.7% in cohort A and B respectively (RR =1.06, 95% CI = 0.20–5.42). Grade III/IV anemia was detected in 5.3% of cohort A patients and 8.0 % of cohort B patients (RR=1.58, 95% CI=0.10–22.99). Ten percent of cohort A patients developed stomatitis grade III/IV while none of cohort B patients had this toxicity (RR=1.06, 95% CI = 0.94–1.17). Hospitalization due to chemotherapy complications (mainly neutropenia) in cohort A and B were 5.3% and 8.3% (RR =1.58, 95%CI = 0.10–22.99). Conclusions: DD two weekly TCA was reported to be feasible in patients with stage II - III breast cancer (Margolis et al. JCO, 2005). This study shows that DD TCA plus G-CSF has comparable toxicity profile with standard TCA regimen with shorter treatment period.

The new primary chemotherapy with S-1 and docetaxel for advanced breast cancer: A first report of N-1 trial.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11560-e11560
Author(s):  
Misako Nakagawa ◽  
Masami Morimoto ◽  
Hirokazu Takechi ◽  
Yukikiyo Kawakami ◽  
Akira Tangoku
Keyword(s):  
Breast Cancer ◽  
Adverse Events ◽  
Advanced Breast Cancer ◽  
Objective Response ◽  
Breast Conservation ◽  
Supportive Therapy ◽  
Advanced Breast ◽  
Primary Chemotherapy ◽  
Her2 Status ◽  
Conservation Rate

e11560 Background: We reported the result of the efficacy and toxicity of S-1 combined with docetaxel (S-1+DOC) in ASCO 2011 (abstract No.1075). It showed good objective response rate (ORR) and some cases showed of complete response (CR) before middle of 8 cycles regimen. But this regimen was difficult to keep compliance of per oral S-1 intake. To improve pathological CR (pCR) rate, we planned a new protocol of primary chemotherapy with S-1+DOC (N-1 trial). Methods: Patients with advanced breast cancer (stage II-IV) were treated with i.v. docetaxel (40mg/m2) on day1 and oral S-1 (80mg as FT/m2/day) on day1 to 14 every 3 weeks for 4 cycles. According to the RECIST criteria, patients with CR were underwent operation, partial response were continued more 4cycles of S-1+DOC. Stable disease or progressive disease cases were changed regimen for EC or Trastuzumab and Paclitaxel (HT) according to their HER2 status. Adequate supportive therapy was provided for typical adverse events. Primary endpoint is a pCR rate. Secondary endpoints are ORR, breast conservation rate and safety. Results: Between 2009 and 2011, Forty-two patients were originally entered. After 4 cycles of S-1+DOC, CR was noted in 6 cases, and PR in 20 cases. 8 cases of SD and 1 case of PD were underwent EC, 4 cases of SD were underwent HT. Among 36 patients who had completed the whole regimen, 30.7% achieved pCR. ORR was 79.4% and breast conservation rate was 97.4%. Patients could keep an intake more than 80% dose of S-1 was 87%. Adverse events over grade3 were peripheral sensory neuropathy, nausea, nail change and neutropenia. Grade 3, 4 of neutropenia was noted in 62%. Conclusions: The new primary chemotherapy with S-1 and Docetaxel is expected to exhibit satisfactory efficacy and showed the possibility of shortened the term of primary chemotherapy. In order to establish this treatment, it is important to proper response assessment.

Acute Myelocytic Leukemia and Chronic Myelomonocytic Leukemia Simultaneously with Resectable Breast Cancer: A Report of two Cases

1992 ◽  
Vol 78 (5) ◽  
pp. 356-358 ◽  
Author(s):  
Luigi Cavanna ◽  
Daniele Vallisa ◽  
Michele Di Stasi ◽  
Fabio Fornari ◽  
Elisabetta Buscarini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Supportive Therapy ◽  
Normal Karyotype ◽  
Chronic Myelomonocytic Leukemia ◽  
Acute Myelocytic Leukemia ◽  
Myelocytic Leukemia ◽  
Response To Chemotherapy ◽  
Fab Classification ◽  
Myelomonocytic Leukemia ◽  
Previous Irradiation

This report describes 2 patients who developed acute myelocytic leukemie (AML) type M2 and chronic myelomonocytic leukemia (CMML) of the FAB classification, respectively 2 months and 2 weeks after diagnosis of operable breast cancer. The patient with AML showed pancytopenia 2 months before the diagnosis of AML, had a normal karyotype, and showed a good response to chemotherapy. The patient with CMML had a normal karyotype, and she was treated with hydroxyurea and supportive therapy. The 2 patients had no previous exposure to irradiation or cytotoxic therapy. These cases show that breast cancer and either leukemia or myelodysplastic syndrome may be associated even without previous irradiation or combination chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document